Logo image of MED

MEDIFAST INC (MED) Stock Fundamental Analysis

USA - NYSE:MED - US58470H1014 - Common Stock

14.06 USD
-0.26 (-1.82%)
Last: 9/23/2025, 8:04:00 PM
14.06 USD
0 (0%)
After Hours: 9/23/2025, 8:04:00 PM
Fundamental Rating

5

Taking everything into account, MED scores 5 out of 10 in our fundamental rating. MED was compared to 36 industry peers in the Personal Care Products industry. MED has an excellent financial health rating, but there are some minor concerns on its profitability. MED is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
MED had positive earnings in each of the past 5 years.
In the past 5 years MED always reported a positive cash flow from operatings.
MED Yearly Net Income VS EBIT VS OCF VS FCFMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

1.2 Ratios

MED's Return On Assets of 1.35% is in line compared to the rest of the industry. MED outperforms 52.78% of its industry peers.
MED has a Return On Equity of 1.68%. This is in the better half of the industry: MED outperforms 61.11% of its industry peers.
MED's Return On Invested Capital of 0.66% is in line compared to the rest of the industry. MED outperforms 44.44% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is significantly above the industry average of 12.97%.
The 3 year average ROIC (38.03%) for MED is well above the current ROIC(0.66%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 1.35%
ROE 1.68%
ROIC 0.66%
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
MED Yearly ROA, ROE, ROICMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

The Profit Margin of MED (0.76%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of MED has declined.
MED has a Operating Margin (0.46%) which is in line with its industry peers.
MED's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 73.84%, MED is doing good in the industry, outperforming 77.78% of the companies in the same industry.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 0.46%
PM (TTM) 0.76%
GM 73.84%
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
MED Yearly Profit, Operating, Gross MarginsMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

10

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MED is creating value.
Compared to 1 year ago, MED has more shares outstanding
Compared to 5 years ago, MED has less shares outstanding
There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MED Yearly Shares OutstandingMED Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MED Yearly Total Debt VS Total AssetsMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.22 indicates that MED is not in any danger for bankruptcy at the moment.
MED has a better Altman-Z score (5.22) than 80.56% of its industry peers.
There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.22
ROIC/WACC0.08
WACC8.79%
MED Yearly LT Debt VS Equity VS FCFMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

MED has a Current Ratio of 4.47. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
MED has a Current ratio of 4.47. This is amongst the best in the industry. MED outperforms 91.67% of its industry peers.
A Quick Ratio of 3.82 indicates that MED has no problem at all paying its short term obligations.
MED has a better Quick ratio (3.82) than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 3.82
MED Yearly Current Assets VS Current LiabilitesMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MED have decreased strongly by -87.18% in the last year.
Measured over the past years, MED shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.59% on average per year.
The Revenue for MED has decreased by -37.62% in the past year. This is quite bad
The Revenue has been decreasing by -3.33% on average over the past years.
EPS 1Y (TTM)-87.18%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-76.09%
Revenue 1Y (TTM)-37.62%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-37.38%

3.2 Future

The Earnings Per Share is expected to decrease by -64.21% on average over the next years. This is quite bad
MED is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -23.25% yearly.
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MED Yearly Revenue VS EstimatesMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
MED Yearly EPS VS EstimatesMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MED is valuated quite expensively with a Price/Earnings ratio of 26.04.
Compared to the rest of the industry, the Price/Earnings ratio of MED is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.41. MED is around the same levels.
The Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 26.04
Fwd PE N/A
MED Price Earnings VS Forward Price EarningsMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -4.16
MED Per share dataMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

MED has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as MED's earnings are expected to decrease with -64.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.21%
EPS Next 3YN/A

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 9.97%, MED is a good candidate for dividend investing.
MED's Dividend Yield is rather good when compared to the industry average which is at 5.62. MED pays more dividend than 97.22% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, MED pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.97%

5.2 History

The dividend of MED decreases each year by -53.42%.
MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
MED Yearly Dividends per shareMED Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

5.3 Sustainability

MED pays out 5.39% of its income as dividend. This is a sustainable payout ratio.
The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP5.39%
EPS Next 2Y-64.21%
EPS Next 3YN/A
MED Yearly Income VS Free CF VS DividendMED Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
MED Dividend Payout.MED Dividend Payout, showing the Payout Ratio.MED Dividend Payout.PayoutRetained Earnings

More info and screens

MEDIFAST INC

NYSE:MED (9/23/2025, 8:04:00 PM)

After market: 14.06 0 (0%)

14.06

-0.26 (-1.82%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners75.57%
Inst Owner Change3.9%
Ins Owners3.3%
Ins Owner Change17.81%
Market Cap154.52M
Analysts46.67
Price Target15.3 (8.82%)
Short Float %19.44%
Short Ratio11.02
Dividend
Industry RankSector Rank
Dividend Yield 9.97%
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP5.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)126.59%
Min EPS beat(2)54.16%
Max EPS beat(2)199.01%
EPS beat(4)4
Avg EPS beat(4)160.04%
Min EPS beat(4)54.16%
Max EPS beat(4)225.1%
EPS beat(8)6
Avg EPS beat(8)101.41%
EPS beat(12)10
Avg EPS beat(12)89.05%
EPS beat(16)13
Avg EPS beat(16)68.5%
Revenue beat(2)2
Avg Revenue beat(2)6.41%
Min Revenue beat(2)4.07%
Max Revenue beat(2)8.75%
Revenue beat(4)4
Avg Revenue beat(4)4.85%
Min Revenue beat(4)3.13%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)2.63%
Revenue beat(12)11
Avg Revenue beat(12)4.12%
Revenue beat(16)14
Avg Revenue beat(16)3.32%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30%
EPS NY rev (1m)0%
EPS NY rev (3m)7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
Industry RankSector Rank
PE 26.04
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF 37.21
P/B 0.72
P/tB 0.72
EV/EBITDA -4.16
EPS(TTM)0.54
EY3.84%
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)0.38
OCFY2.69%
SpS43.72
BVpS19.65
TBVpS19.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.35%
ROE 1.68%
ROCE 1%
ROIC 0.66%
ROICexc 2.44%
ROICexgc 2.44%
OM 0.46%
PM (TTM) 0.76%
GM 73.84%
FCFM N/A
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
ROICexc(3y)95.28%
ROICexc(5y)N/A
ROICexgc(3y)95.28%
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexcg growth 3Y-42.96%
ROICexcg growth 5Y-39.1%
ROICexc growth 3Y-42.96%
ROICexc growth 5Y-39.1%
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 47.98%
Cap/Sales 1.37%
Interest Coverage 250
Cash Conversion 26.07%
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 3.82
Altman-Z 5.22
F-Score5
WACC8.79%
ROIC/WACC0.08
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-87.18%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-76.09%
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-37.62%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-37.38%
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-95.63%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-106.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.21%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-98.06%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%